Illumina collaborates with Nashville Biosciences to accelerate medicines development
Illumina (NASDAQ: ILMN) has announced a multi-year agreement with Nashville Biosciences, a subsidiary of Vanderbilt University Medical Center, to enhance drug development through large-scale genomics. This collaboration will utilize Illumina's next-generation sequencing technology to analyze data from VUMC's extensive biobank, which includes around 250,000 de-identified DNA samples. The initiative aims to identify disease targets, accelerate therapy development, and potentially lower costs, ultimately advancing personalized medicine efforts.
- Strategic partnership with Nashville Biosciences to leverage extensive biobank data.
- Utilization of Illumina's advanced sequencing technology for enhanced drug discovery.
- Potential to accelerate therapy development and reduce associated costs.
- None.
SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Nashville Biosciences, LLC, a wholly-owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced a multi-year agreement to accelerate medicines development through large-scale genomics and the establishment of a preeminent clinico-genomic resource. Using Illumina's next-generation sequencing (NGS) platforms, scientists and researchers will be able to better identify disease associations and targets for intervention by analyzing data derived from VUMC's extensive, high-quality biobank of approximately 250,000 de-identified human DNA samples and associated longitudinal, structured medical data.
Drug discovery is a difficult, expensive, and often time-consuming endeavor, with 90 percent of therapies failing in development. Medicines available today work on just a few hundred targets in the body while around 3,000 genes encode proteins that may be receptive to drug intervention. Genomics-based methods can find targets that are more likely to modify disease in a beneficial way, having the potential to greatly improve the speed of therapy development.
The BioVU® biobank includes a de-identified data set of approximately 250,000 human DNA samples extracted from discarded blood collected during routine clinical testing and consented for research use, aligned with extensive structured clinical data derived from VUMC's electronic medical records over the past 15 years. Illumina will deliver whole-genome sequencing on the samples and upload the data to the Illumina Connected Analytics platform. Together, Nashville Biosciences and Illumina will establish a commercial alliance of multiple pharmaceutical and biotechnology partners to analyze the data for drug discovery and therapy development.
"Nashville Biosciences' enriched biobank data, coupled with Illumina's extensive genomics and bioinformatics expertise, will enable scientists and researchers to generate new insights into disease and develop new medicines," said Joydeep Goswami, Chief Strategy and Corporate Development Officer of Illumina. "Together, we will be able to identify potential targets that could lower costs, improve development timelines, and make therapies more effective for patients."
"Through BioVU® and other initiatives by talented individuals from across our campus, Vanderbilt holds a special place at the forefront of personalized medicine. This agreement with Illumina is a next step, allowing us to utilize its global presence and technology to join with industry partners, realizing our vision to achieve the full promise of clinical and genomic data we have developed," said Jeff Balser, MD, PhD, President and Chief Executive Officer for Vanderbilt University Medical Center and Dean of Vanderbilt University School of Medicine.
Genomic analyses and services anticipated through the collaboration will include genome- and phenome-wide association studies, genomic interpretation (including artificial intelligence-based interpretation), and other analytic approaches that combine clinical and genomic data sets to study human health and disease.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are challenges inherent in developing, manufacturing, and launching new products and services, and our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
Investors:
Salli Schwartz
858.291.6421
IR@illumina.com
Media:
Dr. Karen Birmingham
EMEA: +44 7500 105665
US: 646.355.2111
kbirmingham@illumina.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-collaborates-with-nashville-biosciences-to-accelerate-medicines-development-301456759.html
SOURCE Illumina, Inc.
FAQ
What is the recent collaboration involving Illumina (ILMN)?
How many DNA samples are involved in the collaboration with Nashville Biosciences?
What technology will be used in the Illumina and Nashville Biosciences partnership?
What are the expected outcomes of the Illumina and Nashville Biosciences agreement?
